Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

June 1, 2018June 1, 2018

Lupin Seeking Marketing Approval in Europe for YLB113, Etanercept Biosimilar

News

The European Medicines Agency has accepted for review Lupin’s marketing authorization application seeking approval to market the company’s biosimilar therapy of etanercept, called YLB113. Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ... Read more

May 21, 2018May 21, 2018

Actemra Treatment Linked to Disease Remission in Systemic JIA, German Registry Shows

News

Treatment with Actemra (tocilizumab) is linked to favorable outcomes, namely disease inactivation and remission, in patients with systemic juvenile idiopathic arthritis, according to an analysis of a German autoinflammatory disease ... Read more

March 26, 2018March 26, 2018

Checklist Identifies Kids with Rheumatic Diseases Who Can Receive Chickenpox Vaccine, Study Says

News

Researchers have determined that the chickenpox vaccine is safe for children with juvenile chronic arthritis and other rheumatic diseases undergoing intensive immunosuppressive therapy, as long as they complete a pre-vaccination check-list. ... Read more

February 16, 2018February 16, 2018

American College of Rheumatology Drops Its Early Caution, Supports Biosimilars

News

The American College of Rheumatology has issued a white paper supporting the use of biosimilars as treatments for rheumatic diseases. It had urged caution when the first biosimilars for these disorders ... Read more

February 14, 2018February 14, 2018

Protein Levels in Blood May Help Determine Treatment Intensity in Early Rheumatoid Arthritis

News

Single variants in a specific gene and how they correlate with peptide levels in the blood may help predict treatment requirements in early rheumatoid arthritis. The study, “Vasoactive intestinal peptide ... Read more

January 12, 2018January 12, 2018

Ontario Adds Erelzi to Public Health Plan for Juvenile Idiopathic Arthritis Treatment

News

Ontario has become the third Canadian province to add Erelzi (etanercept), a biosimilar therapy to Enbrel developed by Sandoz, to its public health plan for treatment of polyarticular juvenile idiopathic arthritis and ... Read more

December 15, 2017December 15, 2017

JIA Patients in Remission with Subclinical Joint Inflammation Have Increased Flare Risk, Study Shows

News

The risk of flares increases in juvenile idiopathic arthritis (JIA) patients who are in remission, on medication, and have subclinical inflammation of the joints, a recent study found. Based on ... Read more

December 8, 2017December 8, 2017

Frequency of Remission in Juvenile Idiopathic Arthritis Rises with Disease Duration, Review Study Shows

News

Among patients with juvenile idiopathic arthritis (JIA), those who have a longer disease duration — up to 10 years — are more likely to achieve remission, a review study suggests. ... Read more

December 1, 2017December 1, 2017

JIA Increases Risk of Pregnancy Complications, Swedish Study Suggests

News

Women with juvenile idiopathic arthritis (JIA) who become pregnant should be closely monitored by doctors, as they have an increased risk of both maternal and infant complications, according to a new ... Read more

October 18, 2017October 18, 2017

Physical Activity in JIA Patients Deteriorates with Time, Long-term Study Finds

News

Patients with juvenile idiopathic arthritis undergo a significant deterioration in physical health-related quality of life over time, a 30-year follow-up study shows. The study “Physical Functioning, Pain and Health-Related Quality of Life in Adults with Juvenile Idiopathic Arthritis: ... Read more